GFM Phase II Study of APR-246 Plus Azacitidine in TP53-Mutated MDS and AML

Read expert answers to clinician questions on optimizing the care of patients with CLL in today’s practice, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Susan M. O'Brien, MD John Pagel, MD, PhD Released: January 15, 2021

Expert answers to clinician questions on current challenges in managing patients with myelodysplastic syndromes (MDS), from Clinical Care Options (CCO)

Guillermo Garcia-Manero, MD Rami S. Komrokji, MD Jamile Shammo, MD, FASCP, FACP Released: January 11, 2021

Expert commentary by Lydia Scarfò, MD, providing a European perspective on key studies in CLL and lymphomas from ASH 2020 as reported by Clinical Care Options (CCO)

Lydia Scarfò, MD Released: January 4, 2021

Gain key clinical insights fast, with this short slideset from CCO on optimal management of patients with MM

Brian G.M. Durie, MD Shaji Kumar, MD Thomas G. Martin, MD Philippe Moreau, MD S. Vincent Rajkumar, MD Jesús F. San-Miguel, MD, PhD Released: December 30, 2020